Updated results, multivariate and subgroup analysis confirm improved activity and efficacy for FOLFOXIRI versus FOLFIRI in the G.O.N.O randomized phase III study in metastatic colorectal cancer. - Falcone,A.; Andreuccetti,M.; Brunetti,I. (J Clin Oncol, 2007)